Genomtec S.A.

Business and Financial Review • Jan 10, 2023

Obtaining a valuation of the portfolio of Genomtec'a intellectualproperty rights.With reference to ESPI reports 22/2022 datedSeptember 7, 2022 and ESPI 27/2022 dated November 30, 2022. The Board ofDirectors of Genomtec S.A., based in Wrocław, Poland (the _quot;Issuer_quot;, the_quot;Company_quot;) announces that it received from Dennemeyer Consulting GmbH avaluation report of the intellectual property rights portfolio held byGenomtec.Taking into account the estimation according to DIN/ISO77100 adopted by Dennemeyer, the number of patents granted (9), patentpending applications (26) and the conversion of all patent applicationsinto patents, including trademarks as well as the 14-year protectionperiod of the entire IP (intellectual property) portfolio, the fairvalue of the Company's intellectual property is estimated at EUR 191.336million.According to the report received, the intellectualproperty portfolio held by the Company is valued at EUR 95.663 milliontaking into account a standard 8-year patent term.. It should be notedthat the above amount assumes a discount on patent applicationscurrently pending, and if the current 100% success rate of conversion ofpatent applications into patents is maintained, the amount will amountto EUR 109.335 million. At the same time, it should be taken intoaccount the opinion of Dennemeyer Consulting GmbH that the Company'sintellectual property portfolio is young, and the assumed 8-year periodincluded in the valuation represents only 57% of the shortest of theavailable protection periods for developed inventions. Thus, assuming aconservative calculation period of 14 years (the shortest duration ofpatent protection) and the conversion of all patent applications intopatents, the valuation of Genomtec's IP portfolio amounts to EUR 191.336million.At the same time, it should be taken into account thatthe valuation made should not be equated with the valuation of thecompany, as it only concerns intellectual property and does not takeinto account aspects such as, inter alia, manufactured products,technical schemes, the team, certificates and approvals obtained.Inthe opinion of the Management Board, the valuation of Genomtec'sintellectual property rights portfolio estimated by Dennemeyercorresponds to its fair value. At the same time, the Management Boardemphasizes that the received valuation is the result of the work of anindependent company and should not constitute a recommendation toGenomtec Investors and Shareholders of the final transaction value inthe process of establishing strategic partnerships, selling licensesand/or selling all or part of the owned intellectual property andrelated technology. This Report does not constitute an investmentrecommendation to acquire shares in the Issuer. All financial values aregross.Dennemeyer is a reputable global firm providing legalservices in the areas of patents, trademarks, data verification, projectexecution, audit support during litigation as well as other servicesrelated to intellectual property portfolio management. Dennemeyer is anentity with more than 60 years of tradition and 20 regional officeslocated on 6 continents. The Issuer will inform about the nextsignificant stages of the strategic options review process in currentreports.